ClinicalTrials.gg
RecruitingNCT03347786Updated Jan 17, 2025

Verapamil for Neuroprotection in Stroke

A Phase 1/2 interventional study of 10 mg Intra-arterial Verapamil and 20 mg Intra-arterial Verapamil in Ischemic Stroke, sponsored by Global Neurosciences Institute. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Global Neurosciences Institute · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Apr 2017, registered Nov 2017).
  • Started Apr 2017; still recruiting 9 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
192nd of 364
60 · median 65
Started
2017
with 23 others
Phase 1/2
19 of 480
1 open now
Primary completion
2026-08
later than 29 of 144 live
Registered
200th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 192nd largest by planned enrollment of the 364 interventional ones that give a count, is one of 24 that started in 2017, is one of 19 in phase 1/2, reaches primary completion later than 29 of the 144 other live ones, and was the 200th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • 18 years of age and over
  • Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
  • Candidate for mechanical thrombectomy procedure
  • Onset of symptoms less than 8 hours
  • Measurable neurologic deficit (NIHSS ≥4)
  • Willingness to follow up with rehabilitation therapy
  • Anticipated of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or suspected pregnancy (pregnancy test will be done on women of )
  • Hepatic and/or renal insufficiency (LFT's>3× ; \< 30ml/min)
  • Thrombocytopenia ( count \<75,000/mm3)
  • History of intolerance to verapamil
  • Previous functional disability (modified Rankin > 1)
  • Severe stroke (NIHSS>22)
  • Stuporous or comatose
  • Unlikely to be available for 90 day follow-up
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Verapamil 10 mg Treatment Group

    Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (10 mg) Verapamil.

    Drug: 10 mg Intra-arterial Verapamil

  • Experimental
    Verapamil 20 mg Treatment Group

    Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (20 mg) Verapamil.

    Drug: 20 mg Intra-arterial Verapamil

Interventions

  • Drug10 mg Intra-arterial Verapamil

    Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.

  • Drug20 mg Intra-arterial Verapamil

    Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Bleeding Complications

    Bleeding Complications including: symptomatic intracerebral hemorrhage (sICH), and Hemorrhagic Transformation (HT)

    Time frame: 3 months

  2. Number of Participants with a Serious Adverse Event of Death

    Death

    Time frame: 3 months

Secondary outcomes

  1. Functional Outcomes

    Change in modified Rankin Scale (mRS) Score

    Time frame: 30-days and 90-days

  2. Functional Outcomes

    Change in National Institutes of Health Stroke Scale (NIHSS) Score

    Time frame: 30-days and 90-days

  3. Neuroimaging

    MRI/ CT Scan

    Time frame: 180 Days, 365 Days

07

Study locations

1 of 3 sites recruiting
  • AtlantiCare Regional Medical Center
    Atlantic City, New Jersey 08401, United States
    Recruiting
    • Rob Szapor, MBA, BSN, RN · Contactrszapor@atlanticare.org · 609-345-4000
    • Mandy J Binning, MD · Principal investigator
    • Erol Veznedaroglu, MD · Principal investigator
    • Rudy Rahme, MD · Sub investigator
    • Kenneth Liebman, MD · Sub investigator
    • Zakaria Hakma, MD · Sub investigator
  • St Mary Medical Center
    Langhorne, Pennsylvania 19047, United States
    Not yet recruiting
    • Mary Dawson, Research Manager · ContactMary.Dawson@stmaryhealthcare.org · 215-710-2000
    • Mandy J Binning, MD · Principal investigator
    • Erol Veznedaroglu, MD · Principal investigator
    • Rudy Rahme, MD · Sub investigator
    • Kenneth Liebman, MD · Sub investigator
    • Zakaria Hakma, MD · Sub investigator
  • Crozer Chester Medical Center
    Upland, Pennsylvania 19013, United States
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared as this is a pilot study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2017 (actual). Primary completion is estimated for Aug 2026, 112 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 112 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 20, 2017
StartActual
Apr 20, 2017
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Jan 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03347786
Lead sponsor
Global Neurosciences Institute
Responsible party
Mandy Binning (Director, Global Neurosciences Institute, Global Neurosciences Institute) — Principal investigator
First posted
Nov 20, 2017
Start date
Apr 20, 2017
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion